id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-2604-0008,FDA,FDA-2015-E-2604,"Letter from U.S. Patent and Trademark Office to Gilead Sciences, Inc.",Other,Letter(s),2024-02-28T05:00:00Z,2024,2,2024-02-28T05:00:00Z,,2024-02-28T14:58:14Z,,0,0,0900006486419d62